(HealthDay News) — For patients with gonorrhea, detection of the wild-type serine 91 genotype of the gyrA gene of Neisseria gonorrhoeae is predictive of a successful treatment outcome with ciprofloxacin, according to a study published online in Clinical Infectious Diseases.

Jeffrey D. Klausner, MD, MPH, from the University of California Los Angeles, and colleagues conducted a multicenter prospective clinical study on the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea using a genotypic polymerase chain reaction to assess the status of the N. gonorrhoeae gyrase subunit A serine 91 codon. To determine microbiological cure at 5 to 10 days posttreatment, follow-up specimens were collected.

The researchers found that the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% among 106 individuals with culture-positive infections with the wild-type gyrA serine N. gonorrhoeae genotype.

Continue Reading

“We found that a molecular assay to detect the wild-type serine 91 genotype of the gyrA gene of N. gonorrhoeae was highly predictive of a successful treatment outcome in subjects with gonococcal infections treated with ciprofloxacin,” the authors write. “The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible.”


Klausner JD, Bristow CC, Soge OO, et al. Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study. Clin Infect Dis. doi:10.1093/cid/ciaa596

Marks M and Harding-Esch E. Antimicrobial Resistance in Gonorrhea: Diagnostics to the Rescue. Clin Infect Dis. doi:10.1093/cid/ciaa591